StemX Bio develops human 3D pancreatic microtissues using a patent-pending differentiation protocol to provide researchers with physiologically relevant models that closely mimic the human pancreas. This technology reduces false positives and negatives in drug discovery, accelerating the transition from screening to clinical trials for diabetes therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for diabetes drug discovery often rely on animal models or 2D cell cultures that do not accurately replicate the complexity and function of the human pancreas, leading to false positives and negatives in preclinical studies. Traditional differentiation protocols for generating pancreatic cells from stem cells are time-consuming, inconsistent, and difficult to scale.
Solution
StemX Bio offers human 3D pancreatic microtissues derived from induced pluripotent stem cells (iPSCs) using a chemically defined, patent-pending differentiation protocol. These microtissues contain all relevant pancreatic cell types (α, β, and δ cells) and closely mimic the physiological structure and function of the human pancreas. The 3D models provide a more accurate and predictive platform for drug screening and target validation, reducing the risk of late-stage failures. StemX Bio's differentiation method is robust, reproducible, scalable, and compatible with automation, enabling researchers to generate consistent and high-quality microtissues for their studies.
Target Audience
The primary target audience includes researchers in pharmaceutical companies, biotech companies, and academic institutions involved in diabetes drug discovery and development.
Features
- Human-like 3D pancreatic microtissues containing all relevant cell types (α, β, and δ cells)
- Derived from multiple iPSC and ESC lines to ensure reproducibility
- Fully chemically defined iPSC differentiation protocol
- Scalable and automation-compatible production
- Enhanced physiological relevance and predictive value compared to 2D cultures or animal models
- Reduced time to obtain functional 3D models, eliminating the need for a 40-day differentiation process